Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald R O'Boyle

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Current Opinion in Pharmacology|September 20, 2016
HCV NS5A replication complex inhibitorsMin Gao, Donald R O'Boyle, Susan Roberts
Journal of Virology|May 28, 2003
Specific inhibition of bovine viral diarrhea virus replicaseJin-Hua Sun, Julie A Lemm, Donald R O'Boyle, et al.
Journal of Virological Methods|May 21, 2013
A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvirDonald R O'Boyle, Peter T Nower, Jin-Hua Sun, et al.
Intervirology|April 7, 2005
Replication-competent chimeric hepatitis C virus subgenomic repliconsJulie A Lemm, Mengping Liu, Ronald E Rose, et al.
Antimicrobial Agents and Chemotherapy|February 14, 2013
Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvirChunfu Wang, Jin-Hua Sun, Donald R O'Boyle, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2005
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assayDonald R O'Boyle, Peter T Nower, Julie A Lemm, et al.
Hepatology (Baltimore, Md.)|January 12, 2012
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052Jin-Hua Sun, Donald R O'Boyle Ii, Yan Zhang, et al.
Antimicrobial Agents and Chemotherapy|December 29, 2011
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5AChunfu Wang, Lingling Jia, Haichang Huang, et al.
Antimicrobial Agents and Chemotherapy|June 18, 2014
Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activityChunfu Wang, Lingling Jia, Donald R O'Boyle, et al.
Antimicrobial Agents and Chemotherapy|January 5, 2012
Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052Chunfu Wang, Haichang Huang, Lourdes Valera, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Current Opinion in Pharmacology|September 20, 2016
HCV NS5A replication complex inhibitorsMin Gao, Donald R O'Boyle, Susan Roberts
Journal of Virology|May 28, 2003
Specific inhibition of bovine viral diarrhea virus replicaseJin-Hua Sun, Julie A Lemm, Donald R O'Boyle, et al.
Journal of Virological Methods|May 21, 2013
A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvirDonald R O'Boyle, Peter T Nower, Jin-Hua Sun, et al.
Intervirology|April 7, 2005
Replication-competent chimeric hepatitis C virus subgenomic repliconsJulie A Lemm, Mengping Liu, Ronald E Rose, et al.
Antimicrobial Agents and Chemotherapy|February 14, 2013
Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvirChunfu Wang, Jin-Hua Sun, Donald R O'Boyle, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2005
Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assayDonald R O'Boyle, Peter T Nower, Julie A Lemm, et al.
Hepatology (Baltimore, Md.)|January 12, 2012
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052Jin-Hua Sun, Donald R O'Boyle Ii, Yan Zhang, et al.
Antimicrobial Agents and Chemotherapy|December 29, 2011
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5AChunfu Wang, Lingling Jia, Haichang Huang, et al.
Antimicrobial Agents and Chemotherapy|June 18, 2014
Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activityChunfu Wang, Lingling Jia, Donald R O'Boyle, et al.
Antimicrobial Agents and Chemotherapy|January 5, 2012
Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052Chunfu Wang, Haichang Huang, Lourdes Valera, et al.
Pageof 3